PROCLAIM: Germline Genetic Testing for Prostate Cancer Patients
NCT ID: NCT05447637
Last Updated: 2022-07-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1000 participants
OBSERVATIONAL
2019-11-01
2022-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Identification of Prostate Cancer Genes
NCT00342784
Prostate Cancer Screening in Men With Germline BRCA2 Mutations
NCT02154672
Registry to Measure the Impact of Adding Genomic Testing
NCT02454595
Streamlined Genetic Testing in Prostate Cancer
NCT04359758
The PROFILE Study: Germline Genetic Profiling: Correlation With Targeted Prostate Cancer Screening and Treatment
NCT02543905
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The main goal of this Registry is to assess whether nationally developed guidelines used to select patients for hereditary testing are adequate to identify all patients with prostate cancer who may benefit from testing. Patients will completed a post-test survey regarding their testing experience and clinicians will be asked to provide additional medical records review information via the Clinician Report Form.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Individuals who meet NCCN Testing Criteria
Invitae multi-cancer gene panel
Invitae's multi-cancer panel tests for 84 genes associated with hereditary cancer risk.
Individuals who do not meet NCCN Testing Criteria
Invitae multi-cancer gene panel
Invitae's multi-cancer panel tests for 84 genes associated with hereditary cancer risk.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Invitae multi-cancer gene panel
Invitae's multi-cancer panel tests for 84 genes associated with hereditary cancer risk.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Have prostate cancer at any stage, either actively under treatment or being followed who either: 1. meet NCCN criteria for testing or 2. do not meet NCCN criteria for testing
* Patients who are naive to clinical genetic testing for BRCA1/BRCA2 (single gene panel testing)
Exclusion Criteria
18 Years
90 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Invitae Corporation
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Genesis Healthcare Partners
San Diego, California, United States
Invitae
San Francisco, California, United States
Department of Bioengineering and Therapeutic Sciences, University of California San Francisco
San Francisco, California, United States
Volunteer Faculty, University of California San Francisco
San Francisco, California, United States
Colorado Urology
Lakewood, Colorado, United States
Advanced Urology Institute
St. Petersburg, Florida, United States
Florida Urology Partners
Tampa, Florida, United States
TGH Cancer Institute
Tampa, Florida, United States
North Georgia Urology
Dalton, Georgia, United States
Associated Urological Specialists
Chicago Ridge, Illinois, United States
University Urology Associates of New Jersey
Hamilton, New Jersey, United States
Perlmutter Cancer Center, NYU Langone Health, New York
New York, New York, United States
Associated Medical Professionals
Syracuse, New York, United States
MidLantic Urology
Bala-Cynwyd, Pennsylvania, United States
Carolina Urologic Research Center
Myrtle Beach, South Carolina, United States
Urology Associates, P.C.
Nashville, Tennessee, United States
Urology Partners
Arlington, Texas, United States
Urology Austin
Austin, Texas, United States
Urosurgery Houston
Houston, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
INVPC-1000
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.